Ligand Pharmaceuticals | LGND - Bienes





Bienes Cambio Fecha
Agenus USD 172.69M 13.76M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Anika Therapeutics USD 183.47M 4.09M 2026-06
Arrowhead Research USD 2.11B 156.25M 2026-06
Baxter International USD 19.79B 55M 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Enviri Corporation USD 2.7B 4.56M 2026-03
Gilead Sciences USD 49.36B 6.92B 2026-06
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
Heron Therapeutics USD 252.26M 6.05M 2026-06
Insmed USD 2.1B 26.7M 2026-06
Intrexon USD 73.16M 77.88M 2024-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Karyopharm Therapeutics USD 131.42M 23M 2026-03
Ligand Pharmaceuticals USD 2.19B 653.77M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 129.8B 1.12B 2026-06
Pacira USD 1.24B 35.44M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Veracyte USD 1.49B 49.97M 2026-06